Sydney Barone

Ms. Sydney Barone

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2025 in Medicina
Verified
Journal Article
Open access
PDF file
SBSydney Barone
Sydney Barone
EBEric Bao
Eric Bao
SRStephanie Rothberg
Stephanie Rothberg
JPJose F Palacios
Jose F Palacios
ISIsabelle Smith
Isabelle Smith
NBNicholas Bastidas
Nicholas Bastidas
Background and Objectives: Pediatric patients can acquire scars from both accidental injury and surgical procedures. While scars cannot be avoided if a full-thickness injury occurs, scar visibility may be minimized through a variety of approaches. In this narrative review, we evaluate the current evidence and propose an algorithm for scar management in pediatric patients. Materials and Methods: A review of the literature was performed for scar management techniques for pediatric patients. Management modalities based on the type of scar and dosing, treatment regimen, and safety profiles are described in this article and used to create a scar management algorithm. Results: The initial step to scar management in the pediatric population involves ensuring minimal wound tension, which can be achieved through making the incision along relaxed skin tension lines, and early, minimal tension wound closure. Subsequent treatments to optimize scar care should begin 2–3 weeks following wound closure and involve the application of silicone gel or sheets and scar massaging. When topical products are insufficient, laser therapy can be utilized for the management of immature erythematous or thick scars. When mature, pathological scars form such as atrophic scars, hyperpigmentation, hypertrophic scars, or keloids, a combination of modalities is recommended. These modalities vary by scar type and include retinoids and dermabrasion for atrophic scars; retinoids, hydroquinone, and laser therapy for hyperpigmentation; and pressure therapy, corticosteroids, and laser therapy for hypertrophic scars and keloids. When mature, pathological scars persist following 12 months of non-invasive therapies, surgical excision should be considered. Conclusions: Several treatment options are available to manage scars in the pediatric population depending on scar type.

16 June 2026 in Journal of Craniofacial Surgery
Verified
Journal Article
Closed access
SBSydney Barone
Sydney Barone
EBEric Bao
Eric Bao
SRStephanie Rothberg
Stephanie Rothberg
NBNicholas Bastidas
Nicholas Bastidas
Facial feminization surgery (FFS) reduces gender dysphoria and improves psychosocial well-being in transfeminine patients, but its multiprocedural nature leads to long operative times, increasing anesthetic risk, and limiting daily surgical output. This study analyzes operative times across FFS procedures and describes a comprehensive approach that maximizes efficiency during multiprocedural FFS. 55 patients who underwent FFS from August 2024 through October 2025 were included. A four-person operating team was utilized in all cases. Fourteen patients (25.5%) underwent full FFS, 22 (40.0%) underwent near-full FFS, and 19 (34.5%) underwent partial FFS, totaling 267 procedures (mean: 4.9 procedures per patient). The mean operative time for full FFS was 196.4±39.4 minutes. Frontal sinus setback averaged 50.0±19.1 minutes, compared with 24.4±7.8 minutes for frontal sinus contouring with egg burr alone. Thyroid cartilage reduction averaged 31.6±8.9 minutes, genioplasty averaged 25.7±9.9 minutes, mandibular angle reduction averaged 25.1±9.6 minutes, lip augmentation averaged 8.2±2.2 minutes, fat grafting to the cheeks averaged 5.0±2.3 minutes, and open septorhinoplasty averaged 75.5±22.6 minutes. No intraoperative complications occurred. Two patients (3.6%) developed minor intraoral infections one month postoperatively, both resolving with oral antibiotics. Through deliberate procedural sequencing, concurrent task execution, and a well-trained team, full FFS can be completed efficiently without compromising patient outcomes or trainee education. This approach reduces anesthetic exposure and enables multiple FFS cases within a single day, expanding access in a field where surgical demand exceeds available capacity.

30 June 2026 in Journal of Craniofacial Surgery
Verified
Journal Article
Closed access
SBSydney Barone
Sydney Barone
CWCarol Wang
Carol Wang
JYJina Yom
Jina Yom
EOEmily Orsino
Emily Orsino
SOSammy Othman
Sammy Othman
NBNicholas Bastidas
Nicholas Bastidas
Midface distraction osteogenesis (DO) is used to correct various congenital malformations; however, published reports on associated adverse events remain limited. This study evaluates adverse events associated with midface distractors using the U.S. Food and Drug Administration’s (FDA) Manufacturer and User Facility Device Experience (MAUDE) database. The MAUDE database was queried on August 5, 2025 for reports involving midface distractors from July 2015 through July 2025. Of the 77 total reports, 48 met inclusion criteria after removal of duplicate and unrelated reports. When analyzed individually, 70 unique adverse events were described within these reports. Adverse events were categorized to assess problem types and frequencies. Adverse events were classified as device-related (30.0%), patient-related (58.6%), or both (11.4%). Device-related events predominantly occurred in the postoperative period (75.9%), with breakage being the most common device-related issue (37.9%). Among patient-related events, undercorrection was the most common clinical complication (26.5%) followed by infection (16.3%). Intervention was required for 55.7% of the adverse events, with surgical correction being the most frequent (56.4%). This is the first study to objectively analyze adverse events associated with midface distractors using the MAUDE database. The present findings offer valuable insight for craniofacial surgeons to anticipate and manage complications associated with midface DO.